Your browser doesn't support javascript.
loading
A Two-Antibody Pan-Ebolavirus Cocktail Confers Broad Therapeutic Protection in Ferrets and Nonhuman Primates.
Bornholdt, Zachary A; Herbert, Andrew S; Mire, Chad E; He, Shihua; Cross, Robert W; Wec, Anna Z; Abelson, Dafna M; Geisbert, Joan B; James, Rebekah M; Rahim, Md Niaz; Zhu, Wenjun; Borisevich, Viktoriya; Banadyga, Logan; Gunn, Bronwyn M; Agans, Krystle N; Wirchnianski, Ariel S; Goodwin, Eileen; Tierney, Kevin; Shestowsky, William S; Bohorov, Ognian; Bohorova, Natasha; Velasco, Jesus; Ailor, Eric; Kim, Do; Pauly, Michael H; Whaley, Kevin J; Alter, Galit; Walker, Laura M; Chandran, Kartik; Zeitlin, Larry; Qiu, Xiangguo; Geisbert, Thomas W; Dye, John M.
Affiliation
  • Bornholdt ZA; Mapp Biopharmaceutical, Inc., San Diego, CA, USA.
  • Herbert AS; United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, USA.
  • Mire CE; Department of Microbiology and Immunology, Galveston National Laboratory, University of Texas Medical Branch at Galveston, Galveston, TX, USA.
  • He S; Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada.
  • Cross RW; Department of Microbiology and Immunology, Galveston National Laboratory, University of Texas Medical Branch at Galveston, Galveston, TX, USA.
  • Wec AZ; Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, USA.
  • Abelson DM; Mapp Biopharmaceutical, Inc., San Diego, CA, USA.
  • Geisbert JB; Department of Microbiology and Immunology, Galveston National Laboratory, University of Texas Medical Branch at Galveston, Galveston, TX, USA.
  • James RM; United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, USA.
  • Rahim MN; Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada; Department of Medical Microbiology, University of Manitoba, Winnipeg, MB, Canada.
  • Zhu W; Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada.
  • Borisevich V; Department of Microbiology and Immunology, Galveston National Laboratory, University of Texas Medical Branch at Galveston, Galveston, TX, USA.
  • Banadyga L; Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada.
  • Gunn BM; The Ragon Institute, Cambridge, MA, USA.
  • Agans KN; Department of Microbiology and Immunology, Galveston National Laboratory, University of Texas Medical Branch at Galveston, Galveston, TX, USA.
  • Wirchnianski AS; Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, USA.
  • Goodwin E; Adimab LLC, Lebanon, NH, USA.
  • Tierney K; Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada.
  • Shestowsky WS; Mapp Biopharmaceutical, Inc., San Diego, CA, USA.
  • Bohorov O; Mapp Biopharmaceutical, Inc., San Diego, CA, USA.
  • Bohorova N; Mapp Biopharmaceutical, Inc., San Diego, CA, USA.
  • Velasco J; Mapp Biopharmaceutical, Inc., San Diego, CA, USA.
  • Ailor E; Mapp Biopharmaceutical, Inc., San Diego, CA, USA.
  • Kim D; Mapp Biopharmaceutical, Inc., San Diego, CA, USA.
  • Pauly MH; Mapp Biopharmaceutical, Inc., San Diego, CA, USA.
  • Whaley KJ; Mapp Biopharmaceutical, Inc., San Diego, CA, USA.
  • Alter G; The Ragon Institute, Cambridge, MA, USA.
  • Walker LM; Adimab LLC, Lebanon, NH, USA.
  • Chandran K; Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, USA.
  • Zeitlin L; Mapp Biopharmaceutical, Inc., San Diego, CA, USA. Electronic address: larry.zeitlin@mappbio.com.
  • Qiu X; Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada; Department of Medical Microbiology, University of Manitoba, Winnipeg, MB, Canada. Electronic address: xiangguo.qiu@canada.ca.
  • Geisbert TW; Department of Microbiology and Immunology, Galveston National Laboratory, University of Texas Medical Branch at Galveston, Galveston, TX, USA. Electronic address: twgeisbe@utmb.edu.
  • Dye JM; United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, USA. Electronic address: john.m.dye1.civ@mail.mil.
Cell Host Microbe ; 25(1): 49-58.e5, 2019 01 09.
Article in En | MEDLINE | ID: mdl-30629918
ABSTRACT
Recent and ongoing outbreaks of Ebola virus disease (EVD) underscore the unpredictable nature of ebolavirus reemergence and the urgent need for antiviral treatments. Unfortunately, available experimental vaccines and immunotherapeutics are specific for a single member of the Ebolavirus genus, Ebola virus (EBOV), and ineffective against other ebolaviruses associated with EVD, including Sudan virus (SUDV) and Bundibugyo virus (BDBV). Here we show that MBP134AF, a pan-ebolavirus therapeutic comprising two broadly neutralizing human antibodies (bNAbs), affords unprecedented effectiveness and potency as a therapeutic countermeasure to antigenically diverse ebolaviruses. MBP134AF could fully protect ferrets against lethal EBOV, SUDV, and BDBV infection, and a single 25-mg/kg dose was sufficient to protect NHPs against all three viruses. The development of MBP134AF provides a successful model for the rapid discovery and translational advancement of immunotherapeutics targeting emerging infectious diseases.
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hemorrhagic Fever, Ebola / Ebolavirus / Ferrets / Antibodies, Monoclonal / Antibodies, Viral Limits: Animals / Female / Humans / Male Language: En Journal: Cell Host Microbe Year: 2019 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hemorrhagic Fever, Ebola / Ebolavirus / Ferrets / Antibodies, Monoclonal / Antibodies, Viral Limits: Animals / Female / Humans / Male Language: En Journal: Cell Host Microbe Year: 2019 Document type: Article